Unique ID issued by UMIN | UMIN000022278 |
---|---|
Receipt number | R000025670 |
Scientific Title | Laparoscopic radical hysterectomy using robotic surgical system (da Vinci Surgical System; DVSS) |
Date of disclosure of the study information | 2016/05/11 |
Last modified on | 2020/02/16 13:49:22 |
Laparoscopic radical hysterectomy using robotic surgical system (da Vinci Surgical System; DVSS)
Robot-assisted radical hysterectomy
Laparoscopic radical hysterectomy using robotic surgical system (da Vinci Surgical System; DVSS)
Robot-assisted radical hysterectomy
Japan |
cervical cancer
Obstetrics and Gynecology |
Malignancy
NO
The object of this Study is to assess the efficacy and safety of robotic-assisted radical hysterectomy using DVSS for cervical cancer patient that can be curative. This Study is designed as the Advanced Medical Treatment/Technology Assessment Program B to provide the Clinical Study Report (CSR) based on the primary analysis, for the purpose of regulatory submission to MHLW for the national health insurance technology price listing.
Safety,Efficacy
Confirmatory
Pragmatic
Phase II
success operation with a little blood loss
the operation time, the console time, No. of lymph nodes resected, the appropriateness of extracted specimen, the ratio of blood transfusion, the reserve ratio of autologous blood, the urinary function, the success rate of robot-assisted radical hysterectomy, the rate of conversion to laparotomy, postoperative courses (onset of postoperative oral ingest, duration of postoperative hospital stay), postoperative QOL measured by EQ-5D, overall survival, relapse-free survival, the occurrence of perioperative adverse events, the occurrence of postoperative adverse events, the occurrence of late adverse events, the defect failure of DVSS
Interventional
Single arm
Non-randomized
Open -no one is blinded
Historical
1
Treatment
Device,equipment |
use of the robot for endoscopic surgery
18 | years-old | <= |
Not applicable |
Female
cervical cancer (squamous cell carcinoma FIGO Stages IB1 - llB , or adenocarcinoma FIGO Stages IA2 - IIB without metastasis of lymph nodes and intracorporeal organs)
1) patients having an active double cancer
2) a woman who become pregnant or may become pregnant, or a nursing woman
3) patients with mental disorders
4) morbid obese patients (Body Mass Index: BMI >= 35)
5) patients received neoadjuvant chemotherapy
6) patients that it was judged that it was inadequate to participate in this study due to others
100
1st name | Keiichi |
Middle name | |
Last name | Isaka |
Tokyo Medical University Hospital
Department of Obstetrics and Gynecology
160-0023
6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo
03-3342-6111
isaka@tokyo-med.ac.jp
1st name | Kaori |
Middle name | |
Last name | Nakamichi |
Tokyo Medical University Hospital
Department of Obstetrics and Gynecology
160-0023
6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo
03-3342-6111
n-kaori@tokyo-med.ac.jp
Tokyo Medical University Hospital
None
Self funding
Tokyo Medical University Hospital
6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo
03-3351-6141
d-irinri@tokyo-med.ac.jp
NO
2016 | Year | 05 | Month | 11 | Day |
Unpublished
100
No longer recruiting
2016 | Year | 04 | Month | 05 | Day |
2015 | Year | 12 | Month | 08 | Day |
2016 | Year | 06 | Month | 01 | Day |
2024 | Year | 12 | Month | 31 | Day |
2016 | Year | 05 | Month | 11 | Day |
2020 | Year | 02 | Month | 16 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025670